Učitavanje...
Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon
BACKGROUND. The use of immunotherapeutic agents, specifically immune checkpoint inhibitors (ICIs) for solid malignancies, is rapidly rising, and many new agents and treatment combinations are in development. However, ICIs have a unique side-effect profile of immune-related adverse events (irAEs) com...
Spremljeno u:
| Izdano u: | Ann Surg Oncol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7594106/ https://ncbi.nlm.nih.gov/pubmed/31965370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-08183-0 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|